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ABSTBACT
Objective: The purpose of this study was to investigate the effects of acute betaine (BT)
supplementation, and exercise, on plasma nitrjic oxide (NO) levels and the related
cardiovascular response (CVR). Backgroundl: BT is a nutrient found in foods such as
wheat gefln, bran, spinach, and seafood. It is thought that BT supplementation will
improve athletic performance by, among other pathways, increasing endothelial NO
production. Methods: This study followed a placebo controlled, double-blind, repeated
measures design. Placebo and BT trials were administered in a cross-over, partialty
randomized, and counterbalanced fashion. Subjects consumed either a250ml placebo
(carbohydrate-electrolyte beverage, CHO) or jZ50 ml CHO + 2.5 E BT. Subjects sat for
45 min then cycled for 30 min at 60 rpm with a resistance of 2.5o/o body weight (kg).
Blood was drawn before and 45 min after BT supplementation, and immediately post
exercise, to assess plasma NO. HR and BP w,:re also measured. Statistical Analysis: A
2 x 3 repeated measures ANOVA across treahnents (CHO + BT and CHO) and times
(-45, 0 and 30 min) assessed differences in N0. Another 2 x 5 repeated measures
ANOVA across the same treafinents and times (-45, -15, 0, 15, and 30 min) assessed
differences in HR, BP, and MAP. Significant results were further analyzed using
multiple pairwise comparisons with Bonfenoni adjustments and alpha was set at 0.05.
Results: No significant interactions or differe,nces between goups were found for plasma
NO levels or CVR variables with acute BT supplementation. A significant time effect
(P S 0.013) for all CVR variables was found and expected due to the effect of exercise.
Conclusions: Acute BT supplementation did not increase plasma NO levels or alter
CVR at rest or during light to moderate cycling.
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Chapter I
INTRODI.ICTION
Betaine (BT) is a naturally occurring compound found in many foods such as
wheat gefin, bran, spinach, beets, shrimp and other seafoods (Sakamoto, Nishimura, Ono,
& Sakura, 2002; Zeisel, Mar, Howe, & Holderr, 2003). BT supplementation improves
athletic performance by enhancing metabolisnr when consumed with a carbohydrate-
electrolyte fluid replacement drink. For example, BT supplementation improved selected
anaerobic power performances (Czapla, Pryor, Swensen, &, Craig, unpublished data,
2009; Hoffman et a1.,2009; Maresh el a1.,2007). The ergogenic effect of BT is likely a
product of an ability to donate methyl groups t;hereby upregulating creatine synthesis in
skeletal muscle (Borsook & Dubnoff, 1940;Craig,2004). BT is also an osmolye, which
plays an important role in fluid homeostasis, possibly protecting cells against dehydration
when electrolyte levels or temperatures are extreme (Craig; Sizeland, Chambers, I.ever,
Bason, & Robson, 1993). Even though it is arr osmolyte, current research on BT
enhancing aerobic performance in hot conditions is inconclusive (Armstrong et al., 2008;
Klasing, Adler, Remus, & Calv ert, 2002; Millrard-Stafford, 2005).
In addition to these potential roles, BT has also been theorized to upregulate gene
expression of nitric oxide synthase (NOS) restrlting in increased nitric oxide (NO)
availability (Jallel-Messadek, 2007). NO is a lkey factor in maintaining proper flow-
mediated vascular tone. In addition to causing;vasodilation, NO also inhibits
vasoconstriction and platelet and leukocyte aggregation to vascular endothelium.
Further, NO mediates precursors of inflammation, neurotransmission, muscle contraction,
2glucose uptake and metabolic regulation (Detopoulou, Panagiotakos, Antonopoulou,
Pitsavos, & Stefanadis, 2008; Kingwell, 2000; Mellion et a1., 1981). These functions and
properties make NO a potentially important farctor in cardiovascular health. Research has
demonstrated a positive linear relationship between exercise intensity and NO production
(Pogliagi, Krasney, & Pendergast,lggT; St. Croix, Wetter, Pegelow, Meyer, & Dempsey,
1999). The cardiovascular response (heart rate, blood pressure, and blood flow
distribution) to exercise is directly proportional to intensity (Laughlin, 1999). Although
currently debated in the literature, elevated NO could conffibute to greater hyperaemia in
working muscles, thereby potentially improvirrg exercise performance (Clifford &
Hellsten, 2004; Kingwell, 2000; Tschakovsky & Joyner, 2008).
While the exact pathway of increasing NO via BT supplementation is yet to be
fully elucidated, research shows that BT alters plasma NO. For example, 6 g'd-l of BT
increases resting levels of plasma NO from 28.8 + 3.4 pM to 82.3 L 13.2 pM after one
week of supplementation (Iqbal et al., 2006). Increased NO avaitability through BT
supplementation may be advantageous from both a health (e.g., anti-inflammatory,
cardiovascular benefits, immune and male sexual function) and exercise performance
standpoint (e.g., vasodilation promoting exercise hyperemia results in improved clearance
of muscle metabolites and substrate delivery). However, little is known about the
combined effects of acute BT supplementation and exercise on plasma NO levels.
It is possible that exercise and NO mal,work synergistically to elevate plasma
NO. Accordingly, BT supplementation could benefit both exercise performance and
cardiovascular health through association with NO. The aim of this investigation was to
determine if acute BT supplementation alters resting plasma NO. An additional aim was
to examine the effects of acute BT supplementation combined with exercise on plasma
NO. The final purpose of the study was to determine if acute BT administration (with
potential NO effects) alters the cardiovasculat'response to exercise.
Statement of Pu{pose
The pqpose of this study was to investigate the effects of acute BT
supplementation, and exercise, on plasma NO levels and the related cardiovascular
response.
H)rpothesis
The hypotheses of this study were:
l. Acute supplementation of BT (2.5 gin250 ml CHO solution) increases
resting plasma NO levels more than a 250 ml CHO solution alone after 45
min.
Acute supplementation of BT (2.5 g in 250 ml CHO solution) plus exercise
increases exercise plasma NO levels more than CHO plus exercise.
Acute supplementation of BT (2.5 gin250 ml CHO solution) causes a
different resting cardiovascular response (i.e., HR, SBP, DBP and mean
arterial blood pressure (MAP)) tharr CHO solution alone after 45 min.
Acute supplementation of BT (2.5 gin250 ml CHO solution) plus exercise
will cause a different cardiovascular response (i.e., HR, SBP, DBP and MAP)
to exercise than CHO plus exercise.
Assumptions c,f The Study
BT increased endogenous production of NO by methylating NOS.
2.
3.
4.
42. The 45 min resting period after BT'supplementation allowed for peak
circulating BT.
3. The colorimetric assay measuring nitrate plasma levels were representative of
total NO production.
Delimitations of The Study
1. Exercise consisted of 30 min of cy,;ling at 60 rpm with2.5%o body weight (kg)
pedal resistance.
2. The subjects were healthy, recreationally active college-aged males.
3. A colorimetric nitrate assay was used to determine NO levels in the plasma.
4. Supplementation was a single dose of BT (2.5 g'd-l) in a250 ml aqueous CHO
sblution given 45 min before exercise.
5. Plasma NO was measured 45 min llrior to, immediately before (0 min), and
immediately after the 30 min of ex,ercise.
6. Cardiovascular measures of HR, SllP, DBP and MAP were made 45 and 15
min prior to the exercise bout and at 0, 15 and 30 min during the exercise
bout.
Limitations oll The Study
1. Results may not be generalizable to exercise other than cycling at 60 rpm with
2.5%body weight (kg) pedal resistance.
2. Results may not be generalizable to populations other than healthy,
recreationally active college-aged rnales.
3. Colorimetric nitrate assay techniques may not measure total plasma NO
levels.
54. BT doses, other than 2.5 g'd't ina',250 ml CHO solution, may produce
different NO levels and cardiovascular response to exercise.
5. NO was measured 45 min prior to, immediately before (0 min), and
immediately after the 30 min exercise which may be generalizable to NO
production at other times.
6. Results may not be generalizable t<> cardiovascular responses other than HR,
SBP, DBP and MAP (e.g., blood vessel diameter and stroke volume) or to
measurements taken at other times.
Definition,rf Terins
l. Acute BT supplementation- a single dose of BT (2.5 d plus CHO in a 250 ml
aqueous solution.
2. Healthy college-aged- free from any orthopedic, metabolic, viral, bacterial or
genetic disease and between the ages of 18 and 26 years.
3. Recreationally active- participating;in light to moderate exercise > 3 per week
and not part of, or engaged in, a collegiate sport or periodized endurance or
resistance training program.
4. Cardiovascular response- the HR, IIP and MAP reaction to the stress of
physical activity.
. 5. Ergogenic aid- any substance used with the intention of, or may result in,
improving exerci se performance.
Summ.ary
Although not fully elucidated, the extant literature on BT implies several
ergogenic properties. These may include its role as an osmoprotectant, methyl goup
6donor, and putatively upregulating NOS gene expression. Numerous studies show
physical activity increases NO production. If BT further increases NO availability during
exercise (i.e., a cumulative or synergistic effe,:t), both exercise performance and vascular
health may benefit. The combined effect of acute BT supplementation plus exercise NO
warrants sfudy.
Chapt;er 2
REVIEW OF LITERATURE
lntroduLction
Research on the potential ergogenic effects of BT is at its genesis. Among the
putative ergogenic effects, BT may upregulate NOS gene expression resulting in
increased NO levels, yielding a potential health and exercise performance boon. NO is a
key mediator in vasodilation and vascular tonr:. Vasodilation and corresponding
hyperaemia to working muscles is essential for exercise performance. The chemical and
metabolic properties of BT and NO will be explored in this chapter as well as the
relationship between BT and NO. The specific topics for this review are: (l) betaine, (2)
ergogenic effects of betaine supplementation, (3) nitric oxide, (4) exercise and the nitric
oxide response, and (5) betaine and nitric oxidle.
Betarine
BT is a nanrally occurring compound found in many foods such as wheat genn,
bran, spinach, beets, shrimp and other seafoods (Sakamoto et a1.,2002; Zeisel et a[.,
2003). BT is also endogenously synthesized fiom choline containing compounds via
oxidation pathways (Craig, 2004). Otherwise known as a trimethyl glycine, BT is a
derivative of the amino acid glycine and a quaternary ammonium compound with
zwitterionic properties (net charge of zero and pH 7.0). As a methylamine, BT contains
three chemically reactive methyl goups which allows for methyl group donation (Craig;
Yancey, Clark, Hand, Bowlus, & Somero, 198,2). BT provides transmethylation in the
methionine cycle decreasing the concentration of homocysteine in the body, a role
reserved for only BT or folate.
8Craig(2004) estimated that the average dietary intake of BT in humans is I to
2.5 g.d'r,with the higher end of this range seen in diets high in seafood and whole wheat.
BT is absorbed from the duodenum and peaks in the serum roughly one hour
postprandial, typically reaching 20-70 prmol'L,-r in humans depending on the meal (Craig;
Lever et al., 2002). BT is metabolized fairly quickly in the liver in both single
(0.43 mmol'kg-r dose has an elimination half-life of 14.4 r7.2h) and multiple dosages
(0.43 mmol.kg-I dose every 12 h over a 5 d period has an elimination half-life of 4L.2 +
13.5 h) (Schwahn et al., 2003).
Betaine Metabolism
In the liver, BT is catabolized as a sut,strate by the enzyme betaine-homocysteine
methyltransferase (BHMT, EC2.l.l.5) produr:ing the byproduct dimethylglycine
(DMG). BHMT catalyzes the remethylation c,f homocysteine to methionine thereby
increasing mettrionine, which is required for protein sSmthesis, as a result, this process
decreases homocysteine concentrations. Studiies show that BT provides the necessary
methyl group for methionine to methylate glyr;ocyamine (guanidoacetic acid) in the
production of creatine in skeletal muscle (Borsook & Dubnoff, 1940; Vigneaud,
Simonds, Chandler, & Cohn, 1946). This methylization process posits BT as an
ergogenic aid by increasing the production of creatine in skeletal muscle (Borsook &
Borsook, 1951; Craig,2004; Vigneaud et al., X,946).
When not metabolized, BT acts as an organic osmolyte maintaining osmotic
homeostasis (Alfieri et al., 2006; Caldas, Demont-Caulet, Ghazi, & Richarme,1999;
Olsen, Ramlov, & Westh, 2007; Sizeland, Charnbers, Lever, Bason, & Robson, 1993). In
this capacity, BT plays an integral role in sustaining water balance, cell volume and
9sfructure in vivo. These osmoprotectant propi:rties suggest prevention of dehydration and
protein denaturation, which could theoreticall'y improve aerobic, anaerobic, strength, and
power performance (Craig, 2004).
Betaine and Health Promotion
Betaine has been extensively researched in human and animal clinical studies for
health promoting potential. As discussed in a review by Eklund, Bauer, Wamatu, and
Mosenthin (2005), BT improved carcass composition (lean mass, fat mass ratio) in
porcines, rats, and poultry to name a few (Fenriindez-Figares et a1.,2002; Hayes,
Pronczuk, Cook, & Robbins,2003; Wray-Cahen, Fem6ndez-Figares, Virtanen, Steele, &
Caperna, 2004). BT also improved exercise recovery time in untrained horses (Warren,
Lawrence, & Thompson, 1999). These effects; in animals generated interest in exploring
possible health and performance enhancements from BT in humans.
To that end, BT has been used for the treatment of non-alcohol steatohepatitis,
hepatic ethanol induced seatosis, and decreasing risk factors to heart health (Abdelmalek,
Angulo, Jorgensen, Sylvestre, & Lindor, 2001', Barak, Beckenhauer, Junnila, & Tuma,
1993; Borsook & Borsook, 1951; Graybiel & llatterson, 1951; Mukherjee eta1.,2005).
Recently, Xu et al. (2009) analyzed data from the Long Island Breast Cancer Study
Project and suggested high intake of BT and choline may be a prophylactic strategy to
avoid breast cancer. Conversely, Olthof, van \/ilet, Verhoef, Zock, and Katan (2005)
theorized BT may increase low density lipoprc,tein (i.e. bad cholesterol) concentrations,
however, as reviewed by Zeisel (2006), these results are preliminary and require further
investigation. Wilcken, Wilcken, Dudman, an,d Tr"r.1t (1983) was the first to show that
BT lowers serum homocysteine in subjects with homocystinuria. Interestingly,
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inadequate amounts of BT increase the risk of rlistal colorectal adenoma in females and
exacerbate metabolic syndrome and cardiovascular disease risk (Cho et al.,2OO7;
Konstantinova et al., 2008). It is clear from these shrdies that BT may be involved in a
number of pathways integral to maintaining optimal health.
Ergo genic Effects of Betriine Supplementation
The ergogenic potential of BT is derived from the ability to function as an
osmolyte, methyl donor, and upregulator of enrlothelial nitric oxide synthase (eNOS).
Putative performance enhancements, therefore. include prevention of dehydration,
improved cardiorespiratory functions, increased skeletal muscle creatine concentration,
and increased vasodilation in active muscles via stimulation of eNOS gene expression. ln
addition, an emerging use of BT is for the ability to reduce inflammation. In 2008,
Detopoulou et al. (2008) demonstrated the potential role of BT (>360 mg'd-t)
supplementation to attenuate (10 - L9% decrearse) inflammatory markers in healthy adults
compared to lower doses of BT supplementation (<260 mg'd-r and260 - 350 mg'd-t).
Reduction of inflammatory compounds would benefit cardiovascular health.
Furthermore, sports performance may be enharrced by attenuating recovery periods and
potentially increasing playing time due to reduced inflammation.
Osmoorotectant Role and Effects on Cardiovat;cular Exercise
BT is an osmolyte that defends osmotir; pressure by raising pressure in the
cytoplasm and stabilizing proteins and cell membranes when dehydration, electrolyte
levels, or temperahrres are extreme. In particular, during a dehydration state, osmolytic
compounds such as BT attenuate water loss against larger osmotic gradients (Klasing et
a1.,2002). In animals, BT can protect fish as they swim through waters with varying
1l
degrees of salinity (Virtanen, 1995). In humans, during an exercise bout, a salinity
oscillation effect may occur secondary to hydration levels. Armstrong et al. (2008)
investigated the effects of BT on strenuous rurming and sprinting to exhaustion in a
heated environment (31.1' C). They hypothesized the osmoprotectant and cardiovascular
benefits of BT would improve endurance training in the heat. After a dehydration period,
ten male rurulers were rehydrated with eithbr. I L water (W), W + BT (5 g'L-r), an
electrolyte carbohydrate containing fluid (CH(l), or CHO + BT (5 g'L-l). Subjects ran
for 75 minutes at65o/o VOzmax followed by a timed performance run at 84o/oYOzmaxto
volitional exhaustion. The CHO + BT time to exhaustion was greater than CHO by 32 s
(16%) and W + BT time to exhaustion was grr:ater than W by 38 s (21%). The CHO +
BT solution also increased oxygen consumpti<>n 4-5o/o more than CHO at the same
workloads, thereby effectively increasing energy production via aerobic metabolism.
Interestingly, there was greater plasma volume loss in subjects who consumed W + BT
versus W, even though BT is suggested to attenuate and even protect against plasma
volume loss and dehydration. Investigators sfieculate, however, that chronic BT
supplementation may elicit different results than acute ingestion.
In another study, Millard-Stafford (2005) found cycling performance increased
l0% with a6% CHO solution and l4oh with a 7o/oCHO + BT solution compared to W.
Subjects cycled for 120 min varying between 60 - 75o/o VOzmax followed by a l5 min
time trial. The cycling protocol is representative of typical race-day experiences and
supplementation with CHO + BT was more elfective than CHO or W alone at improving
cycling time trials. Future animal and human studies are needed to elucidate the role of
BT as an osmoprotectant and proponent of cardiovascular exercise.
l2
Other Potential Effects on Aerobic Activity
Human and animal studies show trendr; that BT improves metabolic and chemical
indices important to cardiovascular activity. l'he beneficial mechanisms of BT may
involve affecting plasma lactate metabolism , fatty acid metabolism, protection of citrate
synthases from thermo-denaturation, and decr,:asing hom6cysteine (Craig, 2004).
Researchers ran trained and untrained horses to volitional fatigue then measured blood
lactate post exercise. Supplementation with BT for L4 d reduced plasma lactate at 60 min
of recovery in the untrained horses (Warren et a1,.,1999). These data suggest BT may be
beneficial for lactate metabolism in the untrairred; however, BT was not effective in
trained horses under the same conditions. Although improved lactate recovery in
unffained horses elucidates another possible ergogenic property of BT, the generalization
of results to human performance may be limited.
Other research by Penry & Manore (2Ct08) suggests the ergogenicity of BT
. 
supplementation may improve aerobic perfornrance by decreasing homocysteine, a
byproduct of choline interaction. High levels of homocysteine are produced during long
endurance exercise, these high homocysteine levels might increase BT mediated methyl
metabolism. Further human studies are needed to confirm or refute the role of BT in
endurance exercise performance.
Regardless of any ergogenic potential of BT, Craig (2004) suggested recovery
rehydration with BT would promote blood volume changes, lower LDL and
homocysteine levels, and thereby begin preparation for future training sessions.
Restoring lost fluids, improving cholesterol pr,cfiles, and maintaining safe plasma
homocysteine levels along with exercise should also be advantageous to cardiac health.
Betaine and Anaerobic Performance
Little is known about the exact mechanism(s) by which BT improves "anaerobic"
performance. Studies suggest that in the mitoc;hondria of the liver and kidney, a series of
enzymaticreaction occur by which BT providt)s an essential methyt groups in the
production of creatine via the methionine cycld (Borsook & Dubnoff, 1940; Vigneaud et
al.,1946). Although this has not been established, increases in muscle creatine and
protein slmtheses would provide additional energy and protein synthesis for "anaerobic"
activity theoretically benefiting power, strength, and force output,
Millard-Stafford (2005) found CHO + BT supplementation attenuated loss of
force in isometric knee extension compared to W and CHO after I20 min cycling and 15
min time trial. W lost 16.8-20.802 force, CHO' lost 14.3 - 18.3% force, and CHO + BT
lost I I .l - 14.5yo force compared to baseline nneasures. In other studies using the same
subject population characteristics (recreationally active, college-aged students), Maresh et
al. (2007) and Hoffrnan et al. (2009) explored the relationship between BT
supplementation and "anaerobic" performanc€r and found diverging results. Hoffman et
al. recruited 24 males that underwent 15 d of IIT supplementation (l .25 g in 240 ml
solution twice per day). Subjects wbre tested rln muscle endurance, power, and rate of
fatigue indices, but no improvements in power measures (Wingate anaerobic test, vertical
jump, and bench press throw) or upper body exercises were observed. The researchers
did find BT improved muscle endurance and cluality of repetitions at 90% of the subject's
one repetition maximum during a squat exercise. Interestingly, these benefits were
apparent within only seven days of BT supplementation.
t4
Maresh et at. (2007) had I 2 male subjer:ts, with at least a three month history of
resistance training which included the squat exercise, consume 1.25 g BT with 240 ml
Gatorade twice per day for 14 d. Before and alfter supplementation, the subjects
performed a series of typical power and strengt*r tests. BT significantly increased
isometic squat force by 10.4o/o, isometric benc;h press force by 19.8o/o, and bench press
throw by 13.7%. BT supplementation did not alter muscular endurance (repetitions),
vertical jrmp, or jump squat power. Unlike Hofftnan et al. (2009), the results from
Marsh et al. clearly indicated that BT improves strength and power performance. It
remains unclear, however, why BT had a selective effect rather than a more constant and
positive influence on such measures. Perhaps improvements may be attributed to the
practice effect if the measures (e.g. bench preSs or squats) are part of the subjects training
protocol.
Recently, Czapla et al. (2009, unpublished data) had 16 untrained subjects
perform a series of four cycling sprints (12 s each) after one week of BT supplementation
(1.25 gBT per 295 ml of CHO beverage twice,a day). Peak power average, peak power
maximum, mean power average, and mean po'wer maximum increased by 6.4oh,5.70/0,
5.4o/o, and 4.4o/o, respectively, compared to bar;eline. There were no changes in the
placebo group, which consumed 295 ml of CH[O beverage twice aday. In summary, BT
shows promising results for improving "anaerobic" performance. The exact mechanism
that underlies this effect needs to be further explored.
l5
Nitric Oxide
Furchgott & Zawadski (1984), in their seminal study, discovered endothelial cells
released many "endothelial derived relaxing f?tctors" or EDRF. Subsequent research
showed EDRF to be the highly reactive, short-lived gaseous compound NO. NOS
catalyzes the synthesis of NO from the precursor L-Arginine resulting in the byproduct
L-citrutline. Co-substrates to this reaction include Oz and nicotinamide adenine
dinucleotide phosphate (NADPH). Co-factorsrto this reaction include: flavin adenine
dinucleotide (FAD), flavin mononucleotide (FMN), tetrahydrobiopterin, heme, and
calcium dependent calmodulin (Reid, 1998).
There are three NOS iso4rmes: type I, type II, and type III. Type I or neural NOS,
is equated with muscular function and metabolism and is located in the sarcolemma, bui
also expressed in the brain, peripheral nerves, spinal cord, and sympathetic ganglia. Type
II or inducible NOS, is equated with immune li.rnction involving cytokine stimulation.
Type III or eNOS, is expressed by vascular endothelial cells, smooth and cardiac muscle,
and the brain. Neural and eNOS are constitutively expressed, low output isozyrnes,
however, once synthesized by these isozyrnes, NO reacts rapidly as a signaling
mechanism for both coronary and peripheral hemod5mamic regulation (Kingwell, 2000;
See Reid, 1998, for a complete review).
NO has a variety of important biological functions, among them is a capacity to
cause vasodilation, inhibit platelet and leukoclrte aggregation to vascular endothelium,
inhibit vasoconstriction, and improve immune,function (Kingwell, 2000; Mellion et al.,
1981). It is evident from both human and anirnal studies th at NO specifically induces
vasodilation of the arteriole smooth musculature.
l6
Production of Nitric Oxide
The following is an outline of purported mechanisms in NO release: (l) basal
release from the endothelial cells, (2) the shear force stress on endothelial vascular cell
membranes caused by friction of blood circulation (viscosity), and (3) metabolites and
other substances (e.g., hydrogen ions, carbon <lioxide, oxygen, potassium, ATP,
phosphate and magnesium). Metabolites and r;ubstances from muscle or neural structures
increase NO release, which ditate surrounding vessels, thereby increasing blood flow and
consequently further enhance endotheliat shear force release of NO. Skeletal muscle also
contains both neural and eNOS isozymes allorving for tissue release of NO (Burnett &
Lowenstein, 1992; Joyrer & Tschakovsky 20Ct3; Kobzik, Stringer, Balligand, Reid, &
Stambler, 1995; Martin, Beltran-De1-Rio, Albr:echt, Larenz, & Joyner, 1996; Toda,
1995). NO releasing mechanisms demonstrate situation specific activation, further, the
abundance of NO producing modes indicate itrs importance in maintaining appropriate
blood vessel tone.
Specific NOS isozymes are upregulated under certain conditions. For example,
the constitutive upregulation of inducible NOSI requires gene transcription, which delays
NO production from this isozyme several hours after exposure to stimuli.. eNOS is also a
constitutive form of NOS, active in immediate production of NO. In the vascular system,
for example, eNOS is the primary isoenzyme responsible for NO production secondary to
shear stress and other metabolites such as POz, PCOz, hydrogen ions, potassium,
phosphate, and magnesium. Other purported conditions and pathways that elicit NO
from eNOS include: potassium activation by blood flow as a result from deformation of
cytoskeletal elements, calcium influx in endothelial cells, ATP release from erythrocytes,
t7
bradykinin release, and phosphorylation of a serine residue altering eNOS affinity to
intercellular calcium (Maiorana, O'Driscoll, Titylor, & Green, 2003). Kleinbongard et al.
(2006) discovered a functional eNOS within human red blood cells. This suggests that
erythrocytes have the ability to conffibute to NO production during intense exercise that
results in local hypoxia within active skeletal rouscle mass. Hemoglobin in these areas act
as a sensor to oxygen levels and consequently induce NO bioactivity (Isbell et al., 2008;
Suhr et a1.,2009). The discovery of yet anothi:r pathway highlights the key role of NO in
vasodilation, while reinforcing the idea that exercise training, even in hypoxic states (i.e.,
anaerobically), promotes NO synthesis.
Pharmacokinetics of Niric Oxide Mediated V:rsodilation
The pharmacokinetics of NO-mediated vasodilation was first discovered by
Gruetter, Kadowitz, and Ignarro (1981) in bovine coronary artery studies. NO activates
soluble guanylate cyclase in smooth muscle cells by generating a NO-heme complex
(heme moiety) that binds to it causing a conformational change facilitating the
conversation of 3', 5'-cyclic guanosine triphosphate (GTP) to 3'-5'-cyclic guanosine
monophosphate (oGMP). Elevated intracellular oGMP causes free calcium depletion
from the smooth muscle cytosolic space, thereby decreasing calmodulin activation of
myosin light chain kinase. Limiting the phosporylation of myosin light chains decreases
smooth muscle tone. Cyclic GMP also activates protein kinase G and phosphorylates
heat shock protein 20, both of which mediate lbrce production by inhibiting cross-bridge
formation and cycling (Brophy et al., 2002; Rembold, Foster, Strauss, Wingard, & Eyk,
2000). Archer et al. (1994) has also shown cCiMP-dependent protein kinase-dependant
potassium channel activation causes smooth nruscle relaxation.
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Auto-oxidation kinetics of NO to nitrate and nitrite in aqueous solutions are
dependent upon a number of factors such as the concentration of NO, diffusibility, and
other bioreactafit concentrations. Hemoglobin, related hemoproteins, and methylene blue
inhibit NO (Ignarro, Wood & Wolin, 1984). Other bioreactants and conditions that can
affect NO concentrations are the type and amount of Oz-derived radicals, POz, blood pH,
PCOz, red blood cells (hemoglobin), adenosine triphosphate (ATP), concentration of
transition metals, magnesium, potassium, and thiols. Consequently, the half-life of NO is
not constant; it ranges from 0.05-l s in circulating blood (Kelm, 1999). The short half-
life of NO in the blood necessitates a constant release of NO during physical activity. It
is evident from the short half-life of NO its actions are primarily local and conducive to
rapid diffusion and inactivation.
Chronic aerobic exercise improves cardiovascular health, as it lowers blood
pressure, improves cardiac output, coronary blood flow, capillary density, and cholesterol
profiles. Such exercise also helps prevent atherosclerosis and coronary artery disease
(Thompson,2003). Cardiovascular risk factors such as hypertension, decreased coronary
blood flow and hypercholesterolemia have been associated with impaired NO release
(Kingwell et al., 1997). eNOS upregulation after a relatively short duration of training
may be the link to long-term structural changes that improve cardiovascular health.
Methods to increase upregulation of NOS gene expression should be explored as NO is
beneficial from both a cardioprotective and an ergogenic standpoint.
Exercise and the Nitric Oxide Response
The control of blood pressure is a product of cardiac output and total peripheral
resistance. There are myriad vasomotor control mechanisms throughout the human body
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regulating blood vessel diameter with redundant'and synergistic pathways. In relation to
exercise performance, the regulation of blood flow and corresponding supply of oxygen
and substrates are crucial elements to success. In response to exercise, blood flow in
active muscles increases up to 100 fold (Walloe & Wesche, 1988).
The vasodilatory response to exercise follows the "ascending vasodilation"
phenomena whereby dilation begins at the arterioles and microvessels and propagates
proximally to larger arteries (Green et al., 1996). To adequately perform at desirable
levels, oxygen and substrate supply must meet the demand of the active myofilaments.
This is controlled by vascular tone, blood delivery to the area and oxygen/subsffate
exffaction capacity of target cells. NO appears.to facilitate both vascular tone and blood
delivery processes in coronary and peripheral circulation (Maroun, Mehta, Turcotte,
Cosio, & Hussain, 1995). Performance of physical activity can be positively modulated
by NO because of its integral hemodynamic and metabolic regulatory effects (Kingwell,
2000).
Studies show a direct correlation between production of NO and intensity of
exercise. In five healthy subjects, during an I 1.3 minute cycling bout, Matsumoto et al.
(1994) found exhaled NO levels increased three-fold from resting to maximum exercise
(l1l L 53 ml.min-' to 398 * 164 ml.min-t). Other studies found similar trends in exhaled
NO concentration during moderate, submaximal cycling protocols. For example, Maroun
et al. (1995) found moderate intensity exercise increased expiratory NO from 85
pM.kgr.min-l to 110 pM.kgt.min-lin sedentary adults and 85 pM'kgl'min-r to 450
pM.kgl.min-l i, a, athletic population. Persson, Wiklund, and Gustafsson (1993) showed
expiratory NO increased from 69 nl'min-l to 225 nl'min-l during a submaximal cycling
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protocol. Pogliaghi et al. (1997) found maximal cycling, using 50 watt increments every
3 min until volitional exhaustion, increased exhaled NO from 137.7 r 57.8 ppb'min-r to
544.7 + 387.0 ppb'min-r.
St. Croix et aI. (1999) also demonsffated the more intense the cycling bout, the
greater the amount of NO release. NO production was assessed during cycle ergometry
at rest and at three intensities (30, 60, and 90o/oYOzmax) in nine healthy subjects and
found NO levels tobe 42.5 +.14.7,43.5 + 15.0, 39.1 + 14.0, and44.4 + 12.9 [NOr- +
NOz-], pmol'L-l, respectively. In sum, NO production is stimulated at the onset of
physical activity and the concentration is correlated to intensity.
The wide range of NO variability in response to exercise may be attributed to
researchers using different units of measurement, exercise intensity, dietary control of
NO, collection procedures, and the biological substances collected to obtain NO levels
(e.g., serum, plasma, urine, saliva and expiratory air). Furthermore, there is variability in
the assays used to measure NO, such as measuring nitrite or nitrate levels (stable end
products of NO) or both in serum assays. Additionally, in ventilator measurement
methods there are numerous techniques, many of which can influence NO determination.
A standardized protocol for.all biological mediums for NO measurement needs to be
agreed on within the research community to facilitate inter-study comparison.
Although exercise clearly increases NO production, controversy remains whether
NO is responsible for hyperaemia induced by exercise. In a review by Kingwell (2000)
of five studies using human subjects, the author concluded that NO either plays no role in
exercise hypeiaemia or has a redundant role. A more plausible explanation may be that
NO is part of a synergistic pathway utilizing other metabolites such as adenosine,
2L
prostacyclin, and K*ATPase channels in moderating blood flow to active muscle
(Clifford & Hellsten,2O04; Tschakovsky & Joyner, 2008).
Betaine and Nitric Oxide
NOS gene expression is regulated by a litany of physiological and
pathophysiological stimuli such as mechanical forces, cell growth, cytokines,
lipoproteins, oxidative sfess and growth factors (Searles, 2006). Recently, BT has been
purported to upregulate NOS gene expression through mRNA methylation by both
transcriptional and fiosttranscriptional events (increasing constitutive NOS protein
levels). BT may also stimulate L-arginine or L-lysine biotransformation through either
eNOS or neural NOS en4rmatic activity (Jallel-Messadek, 2007). Numerous stimuli
moderate eNOS mRNA expression in vitro.
Recently, Jallel-Messadek (2007) theorized BT upregulates NOS gene expression
of NO resulting in increased bioavailability. This increase could lead to greater
hyperaemia in working muscles, thereby improving exercise performance. As a methyl
group donor, BT may actively donate its methyl group in the methylafion and
upregulation in NOS gene expression. BT is theorized to affect only constitutive eNOS
and neural NOS isozymes and not the inducible NOS isozyme. While the exact pathway
to increasing NO via BT has yet to be fully elucidated, recent research shows that it does
alter plasma NO. For example, 6 g'd-l of BT increases resting levels of plasma NO from
28.8 * 3.4 pM to 82.3 t 13.2 pM after one week of supplementation (Iqbal et al., 2006).
This is the first study to demonstrate increased NO release via BT supplementation.
Considering the ergogenic and health promoting additive effects of exercise, BT and NO,
future research related to how these factors interact is merited.
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Summary
BT is a promising supplement with potential ergogenic properties as an
osmoprotectant and methyl group donor. In.addition to these properties, BT is theorized
to upregulate NOS gene expression. An increased production of NO is beneficial to both
cardiovascular health and enhancement of exercise performance. NO is an integral
sigualing molecule in maintaining myriad cardiovascular functions and vascular
homeostasis. NO is a key mediator in flow-mediated vasodilation and vascular tone. The
vasodilation and corresponding hyperaemia to working muscles is essential for exercise
performance. Based upon the literature reviewed, research is needed to assess the role of
BT plus exercise in NOS gene expression and its potential for promoting cardiovascular
health and sport performance.
Chapter 3
METHODS
An overview of the study procedures will be discussed in this chapter. The aim of
this study was to assess the effect of BT supplementation and exercise on plasma NO
levels and cardiovascular response. Sections in this chapter include: (1) subjects, (2)
experimental design, (3) procedures, (4) physiologrcal measures, and (5) statistics.
Subjects
Ten healthy college aged males volunteered to participate in the study. AII
subjects were recreationally active, participating in light to moderate exercise > 3 per
week and not part of, or engaged in, a collegiate sport or periodized endurance or
resistance training program. Subjects were excluded if they reported high blood pressure,
history of diabetes, renal disease, current orthopedic injuries that would prevent cycling,
allergies, illness or any other medical reason that may endanger them or affect the quality
of the study. Subjects who chose to participate were made aware of risks, benefits, and
protocols of the study while providing informed consent (Appendix A). A brief medical
history form (Appendix B) andaZ4-hour history form (Appendix C) were filled out by
the subject to ensure subject compliance with exclusion criteria. Subjects did not
consume any caffeine, alcohol, or any other drugs within 24 h of testing sessions and
maintained current physical activity and dietary habits throughout the course of the study.
Subjects completed an overnight fast and did not eat breakfast on the day of testing. To
ensure hydration, subjects drank 12 oz of water prior to sleeping the night before and
again on the moming of data collection. The methods of this study were approved by the
Ithaca College Human Subjects Review Board.
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Experimental Design
This study utilized a placebo controlled, double-blind, repeated measures design.
To limit the influence of diet and relative cycling workload on BT and NO levels, a
crossover design was employed so each participant was his own control. Placebo and BT
(BetaPowerrM Danisco A/S, White Plains, NY) trials were administered in a partially
randomized, counterbalanced fashion to reduce order effects. For the two trials, the
subjects consumed either a250 ml placebo (carbohydrate-electrolyte beverage, CHO) or
a250 ml carbohydrate-elecffolyte beverage with 2.5 gBT (CHO + BT). To ensure
beverage anonymity, all subjects received uniform opaque sport drink bottles with cap
ties broken.
Procedures
Upon subject arrival, 3.5 ml of blood was drawn to assess baseline plasma NO
levels (-45 min). Subjects then consumed either the CHO or CHO + BT beverage and sat
for 45 min. Based upon human digestion pharmacokinetics of BT, 45 min allows BT to
reach peak levels in the plasma (0.65 - 1.3 hrs post-digestion) (Schwahn et al., 2003).
During this time, subjects were free to read, study, or surf the internet. After this 45 min
period, another resting blood sample was taken (0 min). On a Monark (Series 818e,
Varberg, Sweden) cycle ergometer with seat height adjusted to 10-l5o knee flexion,
subjects completed a 30 min cycling bout at 60 rpm with resistance set at2.So/obody
weight (kg). The calculated workload was analogous to light to moderate intensity
exercise. Blood was drawn immediately after the 30 min cycling bout and the subjects
then cooled down for 5 min against light resistance. Subjects completed a second trial in
the alternate condition at the same time of day after waiting 6 to 8 d to allow for adequate
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BT wash out. The same procedures were used for both data collection sessions. All
testing occurred in a temperature controlled laboratory (72'F).
Phlisiological Measures
In the morning and upon subject arrival, euhydration (U'g S 1.025 pG) was
verified using a digital refractometer (KS-0050; Kernco lnstruments, El Paso, TX). The
subject was then fitted with a Polar HR monitor (Model 5610i; Polar Electro, Kemplele,
Finland), and HR data were measured during rest and cycling (i.e., -45, -15, 0, 15 and 30
min). In addition, blood pressure data were collected at the same time intervals as HR
data using auscultation and sphygmomanometer.
Plasma Collection and Nitric Oxide Assay
Venous blood from an anticubital vein was drawn at rest (-45 min, 0 min) and
immediately following cycling (30 min). Blood was collected in citrate containing vials
and immediately centrifuged at 3500 rpm for 10 min at 4" C. Plasma was collected,
aliquoted and stored at -80o C until analysis. The high reactivity and short half-life of NO
make it difficult to measure directly. Therefore, the concentration of inorganic nitrate
(NOr-), a stable end product of NO oxidation, was assayed by a colorimetric method
using the Greiss method in a total NO Nitrate/ Nitrite Assay Kit (Assay Designs Inc.,
Ann Arbor, MI). The mean minimum detectable dose for this assay kit was
0.625 pM'L-r. Samples were ultra-filtrated with 10,000 MWCO fitter.
Statistics
A2x 3 repeated measures ANOVA across treatments (CHO + BT and CHO) and
times (-45,0 and 30 min) assessed differences in plasma NO. A 2 x 5 repeated measures
ANOVA across the ffeatments and times (-45, -15,0, l5 and 30 min) assessed
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differences in SBP, DBP, MAP and HR. Significant results were further analyzedusing
multiple pairwise comparisons with Bonferroni adjustments. When assumed sphericity
was violated, a Greenhouse-Geisser analysis was performed. All statistics were
performed on PASW (v. 17.0) with alpha set at 0.05.
27
Chapter 4
RESULTS
The fotlowing chapter describes the results from examining the effects of BT, and
exercise, on plasma NO levels and cardiovascular responses at rest and during exercise.
Raw data are found in Appendix E. Statistical analyses of data are detailed in the
following subsections: (1) subjects, (2) plasma nitric oxide, and (3) cardiovascular
responses.
Subjects
Ten recreationally active, healthy college-aged males volunteered to participate in
this study. Means + SD for pertinent anthropometric data were in the expected range
(height : 170.0 + 12.4 cm, weight : 78.7 + 1 1.0 kg, and age : 20.2 t 3.6 y). Subjects
completed both trials for this study within 6 to 8 d and both trials were scheduled at the
same time of day for each subject.
Plasma Nitric Oxide
The2 x 3 ANOVA (Group x Time) with repeated measures on the time variable
(i.e., -45 min, 0 min, and 30 min) showed no significant interactions or differences
between groups or time (Table 1). Examining descriptive data (means + SD) in Table 2,
it can be seen that NO was at the lowest point 45 min after BT supplementation. NO also
returned back to pre-BT supplementation levels after 30 min of exercise.
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Table l.
Plasma Nitric O対de ANOVA Surlmary Table
SS     DF     NIIS     F      ′*
Tilne                 674.9       1.6       427.4      2.3       0.13
Tiine*Group         449.9       1.6       285.0      1.5       023
Error                4963.3      26.8        184.9
c}rOup                350.2       1.0       350.2      0.3       0.31
Error            5395.1     17.0      317.4
Note. * Sphericity was not met, Greenhouse-Geisser corrections were applied to all
p - values
Table 2.
Plasma Nitric Oxide
Time (min) No (pM.L-t) Average (pM'L-t)
551±14.0
Rest -45 53.5±12.8
51_9± 11.6
Control46.3±11.7
Betaine 472±12.2
46.8±12.0
Exercise 30
Contro1     60.8±21.1
Betaine    48.2■11.5*
54.5±16.8
Note. Values are mean + SD, x n = 10 except this data point where n : 9
Group
Betaine
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Cardiovascular. Responses
Slzstolic Blood Pressure
The2 x 5 ANOVA (Group x Time) with repeated measures on the time variable
(i.e., -45 min, -15 min, 0 min, 15 min, and 30 min) showed no significant interactions or
differences between groups for SBP (Table 3). There was, however, a significant main
effect for time (F (4,72) : 137 .2, p : 0.00). Descriptive data (means t SD) are
illustrated in Table 4. Multiple pairwise comparisons using Bonferroni adjustments
found SBP at 15 and 30 min was statistically greater than -45 min (p S 0.013), -15 min
(p < 0.013), and 0 min (p S 0.013). SBP at 30 min was also significantly greater than
SBP at 15 min (p S O.Otf). As expected, the 30 min cycling bout beginning at 0 min was
responsible for the main effect of time on SBP.
Diastolic Blood Pressure
A2 x 5 ANOVA (Group x Time) with repeated measures on the time variable
(i.e., -45 min, -15 min, 0 min, 15 min, and 30 min) showed no signiflcant interactions or
differences between groups for DBP (Table 5). There was, however, a significant main
effect for time (F (1.7,30.31= 6.8,p:0.01). Descriptive data (means + SD) are
illustrated in Table 6. Multiple pairwise comparisons using Bonferroni adjustments
found DBP at 30 min was statistically less than -45 min (p < 0.013), -15 min (,1, < 0.013),
and 0 min (p S 0.013). Again, the 30 min cycling bout beginning at 0 min was likely
responsible for the main effect of time on DBP. From 0 to 15 min a 6.4 mm Hg decrease
occurred and a further 8.4 mm Hg drop occurred from l5 to 30 min totaling a 14.8 mm
Hg decrease from resting DBP during exercise which was not expected.
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Table 3.
Systolic Blood Pressure ANOVA Sllmmary Table
SS      DF      NIIS      F      ′
Tiine            49942.3        4        12485.6     137.2        0.00*
TiFne*Group       149.7        4           37.4       0.8        0.74
Error             4939.0       72            91.0
Group              25.0         1            25_0        0_0        0.87
Error          13186.1      18        732.6
Note. *p<0.013
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Table 4.
Systolic Blood Pressure
Time (min) Group SBP (mm Hg) Average (mm Hg)
-45
Control 123.5±12.1
Betaine 124.4±11_5
123.9±11.8
‐ 15
Control 119.0± 8.6
Betaine 122.9±10.4
120.9± 9.0
Control 118.1■0.9
Betaine 121.7±12.0
119.9±10.5
Exercise 15
Control 163.9■21.7
Betaine 161.9±16.1
162.9±18.9*
Control 171.5±19.7
170.g + 19.2*n
Betaine 170.1 ± 8.7
Note. Values are mean + SD, * Greater than other times (-45, -15, and 0; P < 0.013),
# Greater than 15 min (p < 0.013)
30
-l
0
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Table 5.
Diastolic Blood Pressure ANOVA Summary Table
DF NIIS
Time
Time x Group
Error
Group
Error
3320.0
367.3
8837.4
249.6
4250.6
1.7
1.7
30.3
1.0
18.0
1960.7
217.0
290.0
249.6
236.3
6.8
0.8
1.1
こ
0.01**
0.46
0.32
Note.*SpheHcity was■ot met,Greenhouse―Geisser corrections were applied to all
′_ン
"り
θs,**′≦0.013
SS ′*F
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Table 6.
Diastolic Blood Pressure
Time (min) Group DBP (mm Hg) Average (mm Hg)
Rest        -45
Contro1     82.9±9.5
Betaille     83.4±6.7
81_5± 8.1
-15
Control ,   82.0±7.7
Betaine      81.6 ± 9.4
81.8± 85
0
Contro1     82.4±5.7
Betaine      82_9 ± 7.1
82.7± 6.4
Exercise 15
Contro1     73.4±16.
Betaine    79.1±19.2
763±18.0*
Contro1     63.2±11.7
67.9±14.6*
Betaine      72.7 ±17.5
30
Note. Values are mean + SD, * Greater than other times (-45, -15, and 0; p 3 0.013)
35
Mean Arterial Blood Pressure
A,2 x 5 ANOVA (Group x Time) with repeated measures on the time variable
(i.e., -45 min, -15 min, 0 min, 15 min, and 30 min) showed no significant
interactions or differences between groups for MAP (Table 7). There was, however, a
significant main effect for time (F (4,72):6.5, p: 0.00). Descriptive data (means +
SD) are illustrated in Table 8. Multiple pairwise comparisons using Bonferroni
adjustments found MAP at l5 min significantly greater than -15 min (p S 0.013).
Heart Rate
A,2x 5 ANOVA (Group x Time) with repeated measures on the time variable
(i.e., -45 min, -15 min, 0 min, 15 min, and 30 min) showed no significant
interactions or differences between groups (Table 9). There was, however, a significant
main effect for time (F (4,72):325.r,p : 0.00). Descriptive data (means + SD) are
illustrated in Table 10. Multiple pairwise comparisons using Bonferroni adjustments
found HR at 15 and 30 min were significantly greater than -45 min (p < 0.013), -15 min
(p S O.Ot:), and 0 min (p S 0.013). HR was also significantly gteater at 30 min than 15
min HR (p S 0.013). The exercise effect on HR and the upward drift of HR from 15 to 30
min was expected.
Summary
There were no statistically significant interactions, or group or time main effects
for NO. There were no statistically significant interactions or $oup main effects for any
cardiovascular response (SBP, DBP, MAP and HR). All cardiovascular variables
significantly changed over time, specifically, from 0 min to 30 min as the body
expectedly responded to the exercise bout.
Table 7.
Mean Arterial Blood Pressure ANOVA Summaly Table
SS DF 4ヽS F
Time
Time x Group
Error
Group
Enor
1712.8
91.4
4718.8
148.8
5008.1
4
4
72
1
18
428.2
22.9
65.5
148.8
278.2
6.5
0.4
0.00*
0.84
0.470.5
Note. *p < 0.013
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Table 8.
Ⅳ[ean Arterial Blood Pressure
Time (min) Group MAP (mm Hg) Average (mm Hg)
Rest         -45
Colltro1     96.4± 2.7
Betaine    97.1±2.7
96_8± 2.7
…15
Contro1     94.3 ± 2_7
Betaine     95.4±2.7
94.8± 2.7
Contro1     94.3 ± 2.4
Betaine     95_8 ± 2.4
95.1± 2.4
Exercise 15
Control    103.6±4.2
Betaine    106.7±4.2
105.2± 4.2*
30
Contro1     99.3 ± 4.1
Betaine     105.2±4.1
102.3± 4.1
Note. Values ilre mean + SD, * Greater than -15 min (p < 0.013)
0
Table 9.
Heart Rate ANOVA Summary Table
′FSS DF lヽS
Time
Time * Group
Error
Group
Error
89179.1
134.3
4939.0
466.6
11223.6
4
4
72
1
18
22294.8
33.6
68.0
466.6
623.5
325.0
0.5
0.00*
0.74
0.400.8
Note. *p<0.013
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Table 10.
Heart Rate
Time (min) Group HR (bpm) Average (bpm)
Rest        -45
Contro1     68.4±8.9
Betaine     67_5±7.0
68.0■ 7.8
-15
Contro1     71.0■10.3
Betaine    65.2■10.2
67.9■ 10.3
0
Contro1    73.8±10.6
Betaine    67.1 ■ 9.4
70.5± 10.2
Exercise 15
Control    126.7±17.7
Betaine     124.5 ±16.1
125.6±16.9*
Control     136.5±18.4
133.5± 16.6*#
Betaine     130.5■18.7
Note. Values are mean + SD, * Greater than other times (-45, -15, 0, and 15; p < 0.013),
# Greater than 15 min (p 5 0.013)
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Chapter 5
DISCUSSION
The purpose of this study was to investigate the effects of acute BT
supplementation and exercise on plasma NO levels and cardiovascular response.
Previous research has demonsffated increased resting NO levels after 6 g'd-l for one week
of BT supplementation (Iqbal et a1.,2006). Many authors have shown that there is a
positive linear relationship between exercise intensity and NO production (Matsumoto et
aI.,1994; Pogliaghi et al., 1997; St. Croix et al., 1999). However, little is known about
the combined effects of acute BT supplementation and exercise on plasma NO levels,
blood pressure, and heart rate. This chapter elaborates on the findings of this study in the
following subsections: (1) plasma nitric oxide, (2) cardiovascular responses, and (3)
practical implications.
Plasma Nitric Oxide
Iqbal et al. (2006) found chronic BT supplementation (6 g'd-' for one week)
increases plasma NO at rest. The present study found, however, acute BT
supplementation (2.5 g'd-t) does not significantly increase plasma NO levels at rest. The
conflicting results may be a function of supplementation dosage and time whereby the
amount of BT titration, with chronic doses, may enable upregulation of NOS in the blood
vessels. Future research should examine the effect of chronic BT supplementation
similar to Iqbal et al. and exercise on plasma NO.
The results of this study also demonstrated plasma NO did not increase with
exercise. However, many snrdies show a positive linear relationship with exercise
intensity and NO levels during exercise (Maroun et al.,1995; Matsumoto et al., 1994;
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Persson et al., 1993; Pogliaghi et al., 1997, St. Croix et al., 1999). While exercise
intensity is correlated with NO release, the prescribed exercise intensity in this study may
not have been of sufficient intensity to elicit NO release. Goto et al. (2003) compared the
effects of training at three exercise intensities for 30 min in healthy young men and found
moderate intensity (50% VO2max) training enhanced endothelium-dependant
vasodilation while low (25o/o VO2max) and high (75% VO2max) intensities did not. The
added oxidative stress associated with high intensity training may reduce NO
bioavailability, diminishing any vascular effect seen as a result of NO production
(Maiorana et al., 2003). Additionally, low intensity exercise may not provide a
vasodilatory stimulus strong enough to reach a threshold to promote NO release.
NO is diffrcult to measure directly considering the extremely short half life
(ranging from 0.05-1 s in circulating blood; Kelm, 1999). NO is quickly oxidized to the
stable end products nitrite (NOz-) and NOr- which are then typically measured. This
study assayed NO:- levels only, the addition of a NO2- assay may have shown the positive
linear relationship between NO and exercise.
A potential limitation of the current study was measuring plasma NO
immediately after the cycling bout. Based upon the reviewed literature, it is difficult to
ascertain whether this methodological factor would significantly affect measured NO
levels. Studies with similar methodology have shown both significant (Node et al., 1997)
and non-significant (Matsumoto et al., 1994; St. Croix et al., 1999) results. However,
studies linking NO release with exercise intensity typically measured NO during exercise.
Inconsistencies between studies may be attributed to differences in methodology,
specifically, exercise intensity and duration. Studies involving graded exercise or
moderate (>50% VOzmax) to near- maximal or maximal intensities clearly demonstrated
increased NO release (Maroun et al., 1995; Matsumoto et al., 1994; Node et al., L997;
Persson etal.,l993; Pogliaghi et a1.,1997; St. Croix etal.,l999). Studies using longer
exercise duration also show increased NO release (Jungersten, Ambring, Wall, &
Wennmalm,1997). Perhaps a longer duration or higher intensity may have increased NO
production post-exercise in the current study.
Exogenous sources of NOr- from foods with high NO2- or NO3- levels may alter
resting plasma NO measures and potentially exercise NO measures. In the current study,
subjects were instructed to fast 12 hrs prior to testing to limit this effect. When compared
to other studies with similar methodology, resting plasma NO levels were slightly higher
at rest, however, this small difference had no apparent effect on post-eiercise plasma NO
measures.
A fural potential limitation of this study may be the venous blood sampling from
a peripheral site rather than the vascular bed of the active muscle. Local (quadriceps
muscle) increases in NO may not be sufficient to overcome the diluting effect when
circulating throughout the body to be detected at peripheral (anticubital space) sampling
sites. A similar theory was purported in a sfudy by St. Croix et al. (1999) when blood
was drawn at a similar peripheral site.
Cardiovascular Responses
In the curent study, an acute dose (2.5 g) of BT, had no significant effect oh
resting or exercise HR. The results of this study are in agreement with other research
involving BT and HR. For example, Armstrong et al. (2008) found no statistically
significant differences for HR between treatments (W, W + BT, CHO, or CHO + BT)
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after subjects ran in a heated environment at 650/o VOzmax for 75 min followed by a
timed performance run at 84o/oYO2max to volitional exhaustion. In another study, no
differences in HR were observed between groups (PL, CHO + BT, or CHO) when eight
trained cyclist cycled for 120 min alternating between 6ooh and 7 5o/o VO2mil followed
by a l5 min time trial (Millard-Stafford, 2005).
The results of this study show acute BT supplementation (2.5 g has no significant
effect on resting or exercising SBP, DBP and MAP. Similarly, Schwab et al. (2002)
found no significant differences between control and BT groups after a 12 wk (6 g'd-t)
hypoenergetic diet among 42 obese subjects (male : 14) for resting SBP and DBP.
Conversely, Konstantinova et al. (2008) recently demonstrated BT concentration in
plasma is inversely related to components of metabolic syndrome. Among those tested,
SBP and DBP were identified as having such a chronic relationship (-0.73, 95% CI. l-
1.03, -0.431 and -0.86, 95oh CI: [-1.13, -0.59], P < 0.0001, respectively). However, the
impact of the small yet statistically significant improvements in SBP and DBP resulting
from BT supplementation may not be clinically relevant.
It has been well established that HR and SBP, and also blood flow to working
muscles are linearly proportional to exercise intbnsity (Ehrman, deJong, Sanderson,
Swain, Swank, & Womack,2010; Laughlin, 1999). The 30 min cycling bout in the
present sfudy was responsible for a significant increase in SBP and HR. Although
workload was held constant throughout the exercise, steady state was not achieved for
these variables. The significant, but expected increased HR during exercise may be
explained by the cardiac drift effect whereby stroke volume decreases while HR increases
with time during exercise to maintain cardiac output. This effect can begin within about
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10 min of exercising (Coyle & Gonzalez-Alonso, 2001). Dehydration and hlpovolemia
are two leading hypothesis that contribute to cardiac drift, decreased sffoke volume, and
increased HR during exercise (Ehrman et a1.,2010). In the current study, euhydration
(U.g S 1.025 pG) was verified before exercise possibly suggesting dehydration did not
occur. Hydration was not, however, checked agair, following exercise.
Progressive increases in HR due to cardiac drift during exercise may also be
explained by hyperthermia and subsequent increased sympathetic nervous system
activation to maintain BP (Coyle & Gonzalez-Alonso, 2001). Perhaps over the course of
the 30 min cycling bout, to attenuate core body temperature increases, blood flow to the
skin increased. This thermoregulatory vasodilation caused a trend towards decreased
DBP, ultimately threatening MAP. Additionally, subjects may have experienced
muscular fatigue towards the end of the 30 min cycling bout eliciting increased muscle
fiber recruitment. In order to maintain MAP and meet this added metabolic demand, the
cardiovascular control center increased HR and SBP during the cycling bout by releasing
catecholamines from the adrenal medulla. In sum, the combined effects of muscular
fatigue and the vasodilation due to thermoregulation may have challenged MAP
maintenance but HR and SBP significantly increased to compensate and maintain MAP
during the 30 min cycling bout as expected.
Practical Implications
An acute dose (2.5 g) of BT has no cardiovascular effect during rest or 30 min of
lighrmoderate cycling. Additionally, acute BT supplementation did not increase resting
or post-exercise plasma NO levels. While other ergogenic effects may occur with acute
BT supplementation, benefits sought with improved NO production does not appear to
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occur. Although it has not been investigated, future research should explore whether
exercise increases NO levels with chronic BT supplementation. One dose may not be
enough and the impact of BT on NO may require at least several days or a week as seen
under resting conditions in the work of Iqbal et a[. (2006). Further, other resistance and
endurance training modes, intensities, and durations may exhibit different effects of BT
on NO production and should be explored.
Summarv
Within the limitations of this study, acute BT supplementation did not affect
plasma NO levels at rest or immediately after light-moderate cycling or cardiovascular
responses at rest, during, or after exercise. While not studied in this investigation,
chronic BT supplementation may produce different NO levels during exercise and should
be explored. The lack of effect of exercise on NO may be because of insufficient
intensity and duration which appear to play a role in NO production with exercise.
Chapter 6
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
Summary
This study examined the effects of a single dose of BT on resting and exercise
plasma NO levels and related cardiovascular responses (SBP, DBP, MAP and HR). Ten
male, recreationally active Ithaca College students volunteered to serve as subjects in this
study. This study utilized a placebo controlled, double-blind, repeated measures design.
ln a counterbalanced fashion, subjects ingested either 250 ml placebo (CHO) or 2.5 g of
BT + 250 ml CHO beverage then rested 45'min while HR, BP, and plasma NO measures
were taken. After this time, subjects cycled 30 min against Z.S%body weight (kg) at 60
rpm, after which the last plasma NO measure was taken. Subjects completed a second
trial in the alternate condition at the same time of day after waiting 6 to 8 d to allow for
adequate BT wash out.
Plasma NO levels were indirectly measured through a stable end product of
oxidized NO, NOs-. This was determined using the colorimeffic method and Greiss
technique in a total NO nitrate/nitrite assay. A HR monitor obtained HR and BP was
measured by auscultation and sphygmomanometer at rest and during exercise. NO, HR,
SBP, DBP and MAP data were statistically analyzed with a two-way repeated measures
ANOVA for each dependant variable. Acute BT supplementation did not significantly
increase plasma NO levels or alter cardiovascular responses at rest or after lighrmoderate
cycling.
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Conclusions
Results of this study support the following conclusions:
l. Acute consumption of BT (2.5 g does not significantly increase resting or light-
moderate exercise plasma NO levels as indirectly measured by plasma nitrate
levels.
2. Acute ingestion of BT (2.5 d does not significantly alter HR, SBP and DBP
during rest or light-moderate cycling.
Recommendations
The following recommendations for future study are to:
1. Examine the effects of chronic BT supplementation and exercise on NO levels.
2. Include NOz- in the assay to determine plasma NO production or use other
methods of NO detection in vivo (i.e., exhalation) and during exercise.
REFERENCES
Alfieri, R., Bonelli,M.,Cavazzoni, A., Brigotti, M., Fumarola, C., Sestili, P., et al.
(2006). Creatine as a compatible osmolyte in muscle cells exposed to hypertonic
sEess. The Journal of Phys iologt, 5 7 6(Pt 2), 391-4Ol .
Archer, S., Huang, J., Hampl, V., Nelson, D., Shultz,P., & Weir, E. (1994). Nitric oxide
and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K
channel by cGMP-dependent protein kinase. Proceedings of The National
Academy of Sciences of The Uniled States of America,9l(16),7583-7587.
Armsffong,L.E.,Casa, D.J., Roti, M.W., Lee,E.C.,Craig, S.A.S., Sutherland, J.W.,
Fiala, K.A. & Maresh, C.M. (2008). Influence of betaine consumption on
strenuous running and sprinting in a hot environment. Journal of Strength and
Conditioning Research, 2 2, 85 I -60.
Abdelmalek, M., Angulo, P., Jorgensen, R., Sylvesffe, P., & Lindor, K. (2001). Betaine, a
promising new agent for patients with nonalcoholic steatohepatitis. Results of a
pilot study. The American Journal of Gastroenterologlt, 96(9),2711-2717 .
Barak, A., Beckenhauer, H., Junnila, M., & Tuma, D. (1993). Dietary betaine promotes
generation of hepatic S-adenosylmethionine and protects the liver from ethanol-
induced fatty infiltration. Alcoholism, Clinical and Experimental Research, l7(3),
s52-555.
Borsook, H. & Borsook, M. (1951). The biochemical basis of betaine-glycocyamine
therapy. Annals of Western Medicine and Surgery,5(10), 825-829.
Borsook, H. & Dubnoff, J. (1940). Formation of creatine from glycocyamine in the
liver. Journal Biological Chemistry, I 3 2, 559-7 4.
Brophy, C., Woodrum, D., Pollock, J., Dickinson, M., Komalavilas, P., Cornwell, T., et
aI. (2002). cGMP-dependent protein kinase expression restores contractile
function in cultured vascular smooth muscle cells. Journal of Vaicular Research,
39(2),95-103.
Burnett, A., & Lowenstein,C. (1992). Nitric oxide: A physiologic mediator of penile
erection. Science, 2 5 7(5068), 401.
Caldas, T., Demont-Caulet, N., Ghazi, A., & Richarme, G. (1999). Thermoprotection by
glycine betaine and choline. Miuobiologt, 145(Pt 9),2543-2548.
Cho, E., Willett, W., Colditz, G., Fuchs, C., Wu, K., Chan, A., et al. (2007). Dietary
choline and betaine and the risk of distal colorectal adenoma in women. Journal
げ″乃θ助′Jο″α′働″σθ′ルs′ルプθ,99(16),1224-1231.
Clifford, P.S. & Hellsten, Y. (2004). Vasodilatory mechanisms in contracting skeletal
muscle. Journal Applied Physiologt, 97, 393-403.
Coyle, E.F. & Gonza\ez-Alonso, J. (2001). Cardiovascular drift during prolonged
exercise: New perspectives. Exercise & Sport Sciences Reviews,.29(2),88-92.
Craig, S.A.S. (2004). Betaine in human nutrition. The American Journal of Clinical
Nutrition, 80(3), 539-546.
Czapla, R., Pryor, J.L., Swensen, T., & Craig, S.A.S. (2009). Effect of betaine on cycling
power performance. Unpublished data.
Detopoulou, P., Panagiotakos, D., Antonopoulou, S., Pitsavos,C., & Stefanadis, C.
(2008). Dietary choline and betaine intakes in relation to concentrations of
inflammatory markers in healthy adults: The ATTICA study. American Journal of
Cl inical Nutrition, 87(2), 424430.
Ehrman, J.K., deJong, A., Sanderson, B., Swain, D., Swank, A., & Womack, C.
(2010). ACSM's resource manual for guidelines for exercise testing and
prescription. Philadelphia, PA, Lippincott, Williams & Williams, pp. 54-56.
Eklund, M., Bauer, E., Wamatu, J., & Mosenthin, R. (2005). Potential nutritional and
physiological functions of betaine in livestock. Nutrition Research Reviews,
18(l),31-48.
Fernandez-Figares, I., Wray-Cahen, D., Steele, N., Campbell, R., Hall, D., Virtanen, E.,
et al. (2002). Effect of dietary betaine on nutrient utilization and partitioning in
the young growing feed-restricted pig. Journal of Animal Science, 80(2),421-428.
Furchgott, R.F. & Zawadski, J.V. (1980). The obligatory role of endothelial cells in the
relaxation of arterial smooth muscle by acetylcholine. Nature, I288,373-376.
Goto, C., Higashi, Y., Kimur&, M., et al. (2003). Effect of different intensities of exercise
on endothelium-dependant vasodilation in human; role of endothelium-dependant
nitric oxide and oxidative stress. Circulation, 108,530-5.
Graybiel, A. & Patterson, C.A. (1951). Use of betaine and glycocyamine in the treatment
of patients with heart disease: Preliminary report. Annuls of Western Medicine
and Surgery, 5(l 0), 863-7 5.
Green, D.J., O'Driscoll, J.G., Blanksby, G.A., et al. (1996). Control of skeletal muscle
blood flow during dynamic exercise. Sporls Medicine, 2I , 199-246-
Gruetter, C., Kadowitz,P., & Ignarro, L. (1981). Methylene blue inhibits coronary
49
arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium
niffite, and amyl nitrite. Canadian Journal of Physiology and Pharmacology,
59(2),150-156.
Hayes, K., Pronczuk, A., Cook, M., & Robbins, M. (2003). Betaine in sub-acute and sub-
chronic rat studies. Food and Chemical Toxicology,4l(12),1685-1700.
Hofftnan, J., Ratamess, N., Kang, J., Rashti, S., & Faigenbaum, A. (2009). Effect of
betaine supplementation on power performance and fatigue. Journal of The
International Society of Sports Nutrition, 6(l), 7-17 .
Ignarro, L., Wood, K., & Wolin, M. (1984). Regulation of purified soluble guanylate
cyclase by porphyrins and metalloporphyrins: a unifuing concept. Advances In
Cyclic Nucleotide and Protein Phosphorylation Research, 17,267-274.
Iqbal, O., Fareed, D., Cunanan, J., Hoppensteadt, D., Messadek, J., Baltasar F., & Fareed,
J. (2006). Betaine induced release of tissue factor pathway inhibitor and nitric
oxide: Implications in the management of cardiovascular disease. Federation of
American Societies for Experimental Biolog,t Journal, 20(4), ,4'655.
Isbell, T., Sun, C., Wu, L., Teng, X., Vimrri, D., Branch, B., et al. (2008). SNO-
hemoglobin is not essential for red blood cell-dependent hypoxic vasodilation.
Nature Medicine, I 4(7), 773-77 7 .
Jallel-Messadek, L. (2007).Modulation of nitric oxide syrthases by betaines. United
States patent application publication. Pub. No. US 200710213399 Al.
Joyner,M.&Tschakovsky,M.(2003).Nitric oxide and physiologic vasodiladon
human limbs:Where do we go ttom here?OηαグJαη力″r″α′げ4ノJ″
Phッsノοわy,2∂(3),475‐490.
Jungersten,L.,A面bring,A.,Wall,B.,&Wenrhmalm,A.(1997).Both phySical■tness
and acute exercise regulate nitric oxide foll.lation in healthy humans.力ν
“
αげ
タ ル″Pケわ′り ,∂ズ助,760-764.
Kelm,M.(1999)。Nitric o対de metabolism and breakdown.β′οcttJ〃たαθノβ′υヶ Jεα
Иcta,ノイノ(2-3),273-289.
Kingwell,B.(2000).Nitric o対de as a metabolic regulator during exercise:Effects of
trahing in health and exercise.C′′
“
たα′αηグ助 θr′″θ″ノα′P力αr“αθο7ο,α″グ
Phys′οοy,27(4),239-50.
Kingwell,B.A.,Sherrard,B.,Kelllnings,G.L.,et al.(1997).Four weeks of cycle training
increases basal production ofnittic oxide in the foream.И
“
θttθαη力ν
“
α′グ
′りなJο Ow,272,H1070‐7.
51
Klasing,K.,Adler,K.,Remus,J.,&Calvert,C.(2002).Dietary betaine increases
intraepithelial lynphocytes in the duodenunl ofcoccidia―infected chicks and
increases imctional properties ofphagocytes.動θ jb夕r″α′げハウ′″″Jο4,ノ32(8),
2274-2282.
Kleinbongard,P.,Schulz,R.,Rassat T.,Lauer,T.,Dttam,A.,」ax,T.,et al.(2006).Red
blood cells express a inctional endothelial nitric oxide synthase.3わο4fθて7),
2943-2951.
Kobzik,L.,Stringer,B.,Balligand,J.L.,Rcid,M.B_,&Stambler,J.S.(1995).Endothelial
type nitric oxide synthase in skeletal rnuscle flbers:ⅣIitochondrial relationships.
3Jοc力θ
“
Jεα′α″グ3JρPりなたα′Rωθα″εtt Cο
““
ν″Jεα″0′,2fノ,375-81.
Konstantinova,S.,Tell,G.,Vollset,S.,Nygard,o.,Bleie,0.,&Ueland,P。(2008)_
E)ivergent associations ofplasma choline and betaine with components of
metaboHc syndrome in middle age and elderly men and women.動θ力ν〃α′グ
ハリ″J′ο′,fJ∂(5),914-920.
Laughlin,M.(1999).CardiOVascular response to exercise.И″θttσα″力ν〃α′グ
PhソsJοlοy,27【6),S244.
Lever,M.,Sizeland,P.C.B.,Bason,L.M.,Haンman,C.M.,&Chambers,C.T。(1994).
C}lycine betaine and proline betaine in human blood and urine.βJοε乃力ηJεα θ′
3JυりなJεα Иε″,ノ2θθ,259-64.
M」orana,A.,0'DHscoll,G.,Taylor,R.,&Green,D。(2003).Exercise a d the nittic
oxide vasodilator system。身フο /  MediσJ″θ,33(14),1013-35.
ⅣIaresh,C.Ⅳl.,Farrell,ヽ1.J.,Kraenler,W.J.,Yalmamoto,L.M.,Lee,E.C.,A111lstrOng,
L.E.,Hatfleld,D.L.,Sokmen,B.,Dias,J.C.,Spiering,B.A.,Anderson,J.A.,&
VOlek,Jo S.(2007).The effects ofbetaine supplementation on strength and power
perforlnance.滋清εJ′θα″グルJθ″σθ J″シOrなα″dExθκおθ,39(5),S101.
Maroun,M.,Mehta,S.,Turco■e,R.,Cosio,M.,&Hussain,S.(1995).Effects ofphysical
conditioning on endogenous nitric o対de output during exercise.力ν
“
αげ
タ ル″PAysがり ,7ズo,1219‐1225.
Martin,c.,Beltran―D l―Rio,A.,Albrecht,A.,Lorellz,R.,&」oyner,M.(1996).Local
cholinergic llnechanisms rnediate nitric oxide‐dependent flow―i duced
vasorelaxttion in宙廿o.動θИ
“
θガcα″力ν
“
α′グPhアSJο′οy,27θ(2),H442…H446.
Matsumoto,A.,Httata,Y.,Momomura,S.,Fttita,H.,Yao,A.,Sata,M.,et al.(1994).
Increased nitric oxide production during exercise.五α′σθ′,3イJ(8901),849-850.
Mellion,B.,Ignarro,L,Ohlstein,E.,Pontecorvo,E.,Hyman,A.,&Kadowitz,P.(1981).
Evidence for the inhibitory rble of guanosine 3', S'-monophosphate in ADP-
induced human platelet aggregation in the presence of nitric oxide and related
vasodilators. B lood, 57(5), 946-955.
Millard-Stafford, M. (2005). Fluid replacement in the heat: Effects of betaine. Medicine
and Science in Sports and Exercise,3T(5),528.
Mukherjee, S., Bernard, T., Schafer, D., Barak, A.J-, Sorrell, M.F., & Tuma, D.J. (2005).
Impact of betaine on hepatic fibrosis and homocysteine in non-alcoholic
steatohepatitis-A prospective cohort study. Hepatologt, 42, 610A.
Node, K., Kitakaze, M., Sato, H., Koretsune, Y., Katsube, Y., Karita, M., et al. (1997).
Effect of acute dynamic exercise on circulating plasma nitric oxide level and
correlation to norepinephrine release in normal subjects. The American Journal of
Cardiology, 7 9(4), 526-528.
Olthof, M.R., van Vliet, T., Verhoef,P.,Zock, P.L,, & Katan, M.B. (2005). Effect of
homocysteine-lowering nutrients on blood lipids: results from four randomised,
placebo-controlled studies in healthy humans. PLoS Medicine, 2(5), e135.
Olsen, S., Ramlsv,H., & Westh, P. (2007). Effects of osmolytes on hexokinase kinetics
combined with macromolecular crowding: Test of the osmolyte compatibility
hypothesis towards crowded systems. Comparative Biochemistry and Physiolog,t.
Part A, Molecular & Integrative Physiolog, 148(2),339-345.
Penry, J. & Manore, M. (2008). Choline: An important micronuffient for maximal
endurance-exercise performance? International Journal of Sport Nutrition and
Exercise Metabolism, I 8(2), l9l -203.
Persson, M.G., Wiklund, N.P., & Gustafsson L.E. (1993). Endogenous nitric oxide in
single exhalations and the change during exercise. American Review of
Resp iratory Dis eas e, I 4 8(5), l2L0-4.
Pogtiaghi, S., Krasney, J., & Pendergast, D. (1997). Effect of gravity on lung exhaled
nitric oxide at rest and during exercise. Respiration Physiologt, 107(2),157-164.
Rembold, C., Foster, D., Strauss, J., Wingard, C,, & Eyk, J. (2000). cGMP-mediated
phosphorylation of heat shock protein 20 may cause smooth muscle relaxation
without myosin light chain dephosphorylation in swine carotid artery. The
Journal of Physiology, 524(Pt 3), 865-878.
Reid, M. (199S). Role of nitric oxide in skeletal muscle: Synthesis, distribution and
functional importance . Acta Physiologica Scandinavica, 162(3), 4OL'409.
Sakamoto, A., Nishimura, Y., Ono, H., & Sakura, N. (2002). Betaine and homocysteine
concentrations in foods. P ed ia trics Internaliona l, 4 4(4), 409 -413 .
53
Sizeland, P., Chambers, S., L€ver, M., Bason, L., & Robson, R. (1993). Organic
osmolytes in human and other mammalian kidneys. Kidney International,43(2),
448-453.
Schwab, U., T6rr0nen, A., Toppinen, L., Alfthan, G., Saarinen, M., Aro, A., etal. (2002).
Betaine supplementation decreases plasma homocysteine concentrations but does
not affect body weight, body composition, or resting energy expenditure in human
subjects. The American Journal of Clinical Nutrition, 76(5),961-967 .
Schwahn, B., Hafrrer, D., Hohlfeld, T., Balkenhol, N., Laryea, M., & Wendel, U. (2003).
Pharmacokinetics of oral betaine in healthy subjects and patients with
homocystinuria. British Journal of C linical P harmacology, 55( I ), 6- I 3.
Searles, C.D. (2006). Transcriptional and posttranscriptional regulation of endothelial
nitric oxide synthase expression. American Journal of Physiologt and Cell
Physiologt, 2 9 l, 803-816.
St. Croix, C., Wetter, T., Pegelow, D., Meyer, K., & Dempsey, J. (1999). Assessment of
nitric oxide formation during exercise. American Journal of Respiratory and
Critical Care Medicine, 159(4), I 125-1 133.
Suhr, F., Porten, S., Hertrich, T., Brixius, K., Schmidt, A., Platen, P., et al. (2009).
Intensive exercise induces changes of endothelial nitric oxide synthase pattern in
human erythrocyte s. Nitric Oxid e : B io I o gt and Chemis t ry, 2 0(2), 95- I 03.
Thompson, P. D. (2003). Exercise and physical activity in the prevention and treaftnent
of atherosclerotic cardiovascular disease: A statement from the council on clinical
cardiology (subcommittee on exercise, rehabilitation, and prevention) and the
council on nutrition, physical activity, and metabolism (subcommittee on physical
activity). Arteriosclerosis and Thrombosis Vascular Biologt, 23, e42-e49.
Toda, N. (1995). Regulation of blood pressure by nitroxidergic nerve . Journal of
Diabeles and its C omp lica t ions, 9(4), 200-202.
Tschakovsky, M.E. & Joyner, M. J. (2008). Nitric oxide and muscle blood flow in
exercise. Appl ied Physiologt, Nutrilion, and Metabolism, 3 3 (l), I 5 I -6 l.
Wallse, L., & Wesche, J. (1988). Time course and magnitude of blood flow changes in
the human quadriceps muscles during and following rhythmic exercise. The
Journal of Physiologt, 40(5), 257 -273.
Warren, L., Lawrence,L., & Thompson, K. (1999). The influence of betaine on untrained
and trained horses exercising to fatigue. Journal of Animal Science, 77(3),677-
684.
54
Wilcken, D., Wilcken, B., Dudman, N., & Tyrrell, P. (1983). Homocystinuria- the
effects of betaine in the treatment of patients not responsive to pyridoxine. The
New England Journal of Medicine, 309(8),448-453.
Wray-Cahefl, D., Fernilndez-Figares, I., Virtanen, E., Steele, N., & Caperna, T. (2004).
Betaine improves growth, but does not induce whole body or hepatic palmitate
oxidation in swine (Sus scrofa domestica). Comparative Biochemistry and
Physiology. Part A, Molecular & Integrative Physiolog, 137(l), 131-140.
Vigneaud, V., Simonds, S., Chandler, J.P., & Cohn, M. (1946). A further
investigation of the role of betaine in transmethylation reactions in vivo. Journal
of Biology and Chemistry, I 56,639-48.
Virtanen, E. (1995). Piecing together the betaine ptnzle. Feed Mix, 3, I2-7 .
Xu, X., Gammon, M., Zeisel, S., Bradshaw, P., Wetmur, J., Teitelbaum, S., et al. (2009).
High intakes of choline and betaine reduce breast cancer mortality in a
population-based study. The Federation of American Societies for Experimental
B iolog,' Journal, 2 3(ll), 4022-4028'
Yancey, P., Clark, M., Hand, S., Bowlus, R., & Somero, G. (1982). Living with water
stress: Evolution of osmolyte systems. Science, 21 7(4566), 1214-1222.
Zeisel, S.H. (2006). Betaine supplementation and blood lipids:,fact or artifact? Nutrition
Review, 64(2),77-9.
Zeisel, S.H., Mar, M.H., Howe, J.C., & Holden, J.M. (2003). Concentrations of choline-
containing compounds andbetaine in common foods. Journal of Nutrition,
I 33(5), l3o2-7 .
APPENDX A
lnformed Consent
Effect of Betaine Supplementation and Exercise on Plasma Nitric Oxide
1. Purpose of the Study: The purpose of this study is to examine the effect of betaine, a
natural ingredient found in food, and exercise on blood plasma nitric oxide levels.
Danisco, the maker of BetaPower orbetaine, will provide the betaine and other funds
needed for this project.
2. Benefits: You may benefit from participating in this study because you will get first
hand experience on how scientific data are collected and know your resting nitric oxide
levels. Your participation will also benefit the researchers, who are learning how to
conduct a scientific study. Last, it is hoped that the data, and the subsequent publications
generated from it, will benefit the scientific community.
3. Your Participation Requires you to be at least l8 - 27 years old and in good health.
You will be contacted via email to meet several days before data collection in the
Exercise Physiology Laboratory in CHS 303. You wiH complete a health history
questionnaire; it is possible that you may be excluded from exercising if health risks are
identified in this questionnaire. Your bicycle seat height will also be determined and you
will be given written insffuctions on how to come prepared for data collection if you are
eligible to participate. To ensure hydration, you will drink 12 oz of water before going to
bed the night before and 12 oz of water in the morning prior to reporting to CHS 303.
For the following two weeks, you will visit the lab in the morning following an ovemight
fast, your last meal can be no later than 12 am the night before. Upon arrival, I will
assess hydration levels through a urine sample. Then, I will draw a 3.5 ml sample of
venous blood from an anticubital vein in your arm. I will follow the procedures used by
the Cayuga Medical Center. The blood sample will be used to determine your plasma
nitric oxide level. Similar blood samples will also be drawn 45 minutes after ingestion of
the supplement and at the end of the cycling exercise.
After the first sample is drawn, you will consume up to 250 ml aqueous betaine solution
(l%betaine or 2.5 grams). After consuming the betaine, you will remain in the
laboratory in a seated position for 45 minutes. You are free to read, study, or surf the
internet while in the lab. You will then cycle at a cadence.of 60 rpm at a relative
resistancb of 2.5% body weight (kg) for 30 minutes. I will draw blood samples at the
aforementioned times. In total, three 3.5 ml samples or 10.5 ml in total will be drawn per
session. Each visit to the lab will take approximately 1.5 hours (3 hours total time).
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4. RIsks of Participation:There are no known risks associated with the solutions
provided to you.The risks associated with the bicycle test include skeletal muscle ittury
and possibly a cardiac event,which could be fatal. The chances of a cardiac event are
low lll your age group.You rnay also have sore rnuscles 24 to 48 hours a■er the t sts;the
foreallll region that is lanced inay also be tender for a few days. The study involves
venipuncture,which will be done with aseptic techniques to avoid risk ofinfection atthe
puncture site.To llllnilnize risks,you will wa1111-up and cool―down before and after ea h
test. If you feel poolly du五ng the test,you rnay tell■linate it at any tilne.The technicians
will promptly pro宙de standard irst aid procedures in the event you are ittured.Since
there will be at least h〃o researc  technicians present du五ng any t s ,those not involved
with illlllmediate care will ca11 91 l to seek additional assistance ifwarranted_
5。 Compensation for lniury:Ifyou suffer an ittury that requires any treatment or
hospitalization as a direct result ofthis study,the cost ofsuch care is your responsibility.
If you have insurance,you lnay bill your insurance compally.Ithaca College and the
investigator will not pay for any care,lost wages,or provide other compensation.
6.If you would like more informadon aboutthis study at anytime p五or t ,dur ng,or
following the data collection,you may contact Luke Pryor atlprvoI当ら山堅ュ墾坦Or
814.380.4359 or Dr.Tom Swensen attswensen@ithaca.edu or 607.274.3114.
7. Withdrawal froIIl the study:Participation in this study is voluntary and you llnay
withdraW at any time ifyou so choose.You will not be penalized for withdrawing and
will still be eligible for extra credit.
8。 Confidentiality:hfollllation gathered du五ng this study will be maintained in
complete confldence.(Dnly the researchers will have access to this infollllatiOn,which
will be stored in a locked cabinetin room 320 in the Center for Health Sciences at lthaca
College or on password protected computer. You and your name wili never be associated
with this infollllation in any hture disclosures. To irther insllre confldentiality,all flles
will be number coded and data collection insmments will be kept separately from
lnfolllled Consent FollllS and Sign‐up sheets. There will also be a separate follll for
signing up for extra credit,which will be kept separately貴om all other folllls.
I have read and understood the above document. I agree to participate in this study and
realize that l can withdraw at anytime.I also understand that l can and should address
quesdons related to this study at any time to any ofthe researchers involved.I also ve五fy
that l anl atleast 18 years ofage.
Your Name (please print)
56
Your Siguature Date
APPENDⅨ B
Medical Historv Forln
Name:
Age: Weight: Sex:
MedicaVHealth History (please check all that
[ ] Heart/Disease t
[ ]Stroke t
[ ] Heart Murmur t
[ ] Skipped, rapid or irregular heart rhythms
ankles, or feet
[ ] High Blood Pressure
[ ] High Cholesterol
[ ]Rheumatic Fever
[
[
[ ] Other conditions/comments: (please explain)
Present Symptoms (please check all that have applied within the last six months)
[ ] Chest pain [ ] Ankle/Leg Swelling
[ ] Shortness of Breath
attention
[ ] Joint/muscle injury requiring medical
[ ] Lightheadedness [ ] Allergies (if yes, please list)
[ ] Heart Palpitations [ ] Loss of consciousness
[ ] Illness, surgery, or hospitalization [ ] Other conditions (please explain)
Current medications (please list all medications presently being taken)
Are you taking any supplements that are said to increase nitric oxide levels? If so,
please list.
applv)
] Lung Disease
I Diabetes
lEpilepsy
[ ] Injuries to back, hips, knees,
] Renal Disease
] Allergic reactions to Latex
57
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Exercise Habits
Do you presently engage in physical activity?
If so, what type of exercise? [ ] Aerobic [ ] Strength Training I
How hard do you exercise? [ ] Easy [ ] Moderate
How many times a week do you work out on average?
How many times a day do you work out on average?
Have you ever had any discomfort, shortness of breath, or pain while exercising?
[ ]Yes [ ]No
Sleep Patterns
On average, how many hours do you sleep per night?
Would you say you have good sleeping pattems? t lYes [ ]No (explain)
[ ]Yes lNo
I Both
lHard
APPENDⅨ C
24-Hollr Health Historv Fol■■1
Name:
Current Health Status (please check all ttrat apply)
[ ]SOre LOat
[ ]ChillS
[ ]Cramping
[ ]ShOrtness of Breath
Did you drink 12 ounces of water last night?
Did you drink 12 ounces of water this morning?
Have you consumed alcohol in the last 12 hours?
Date:
[ ]Nausea
[ ] Body Ache
[ ]Nasal Drip
[ ] Chest Pain
Diet
[ ]Headache
[ ] Lethargy
[ ] Muscle Aches
[ ] Dizziness
[ ]Yes   [ ]No
[ ]Yes   [ ]No
[ ]Yes   [ ]No
Have you used caffeine or nicotine in the last three hours? [ ] Yes [ ] No
Did you eat any food in the last twelve hours? [ ]Yes [ ]No
Ifso, please list:
Has your diet changed drastically since the last exercise test? [ ] Yes [ ] No
If so, please describe:
Please describe your last meal and the time of day:
59
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Exercise
Have you exercised in the last24 hours? [ ]Yes [ ]No
If so, please describe:
Has your exercise routine changed at all since the last test? [ ] Yes [ ] No
If so, please explain:
Over-the-Counter and/or Prescription Drug Use
Have you taken any over the counter drugs (e.g., cold meds) in the last24 hours?
[ ]Yes [ ]No
Has there been any change in your use of prescription drugs? [ ] Yes [ ] No
If so, please explain:
Injury
Have you experienced any physical pain in the last 24 hours? [ ] Yes [ ] No
If so, please explain:
Is there any physical ittury we ShOuld know about before you perfollllthe test?
[ ]Yes[]No
If so, please explain:
61
Sleep Pattern:
Has your sleep pattern changed since the last exercise test?
Do you feel drowsy, tired, or run down at this time?
[ ]Yes
[ ]Yes
[]No
[]No
If so, please describe:
Has there been any change since the last exercise test that you feel could compromise
your performance on today's exercise test?
[ ]Yes   [ ]No
If so, explain:
Other questions/coniments/concerns please state below.
APPENDIX D
Pre-Test Insffuctions
Test Date: Test Time:
Your performance depends upon the adherence of these instructions:
1. Do not eat 12 hours before your lab visit.
2. Avoid over-the-counter medications for the 12 hours preceding the lab visit.
(However, cancel the appointment if you are ill and treat yourself accordingly; we
can always reschedule)
3. Please, sustain your same lifestyle habits (eating, exercise, medication, etc.)
between tests.
4. Bring something to read or study to help keep you occupied during the lab visit.
5. Do not drink alcohol for l2 hours before the test.
6. Do not use stimulants such as caffeine (e.g., coffee) or nicotine (i.e., cigarettes)
for three hours preceding the test
7. Wear comfortable clothing and appropriate shoes during the test. (i.e., shorts, t-
shirt, and sneakers EIre recommended)
8. To ensure hydration prior to the test, drink f 2 ounces of water before going to bed
the night before (Saturday) and 12 ounces of water in the moming before
reporting to CHS 303.
62
We thank you for your cooperation!
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